Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) FCF Margin (2016 - 2025)

KalVista Pharmaceuticals' FCF Margin history spans 7 years, with the latest figure at 330.18% for Q2 2020.

  • On a quarterly basis, FCF Margin rose 3845.0% to 330.18% in Q2 2020 year-over-year; TTM through Jul 2024 was 1103.11%, a N/A change, with the full-year FY2025 number at 1394.56%, down 121602.0% from a year prior.
  • FCF Margin hit 330.18% in Q2 2020 for KalVista Pharmaceuticals, up from 831.26% in the prior quarter.
  • Over the last five years, FCF Margin for KALV hit a ceiling of 1202.83% in Q1 2018 and a floor of 75257.14% in Q1 2016.
  • Historically, FCF Margin has averaged 5403.84% across 5 years, with a median of 368.63% in 2019.
  • Biggest five-year swings in FCF Margin: plummeted -1484286bps in 2016 and later skyrocketed 573791bps in 2018.
  • Tracing KALV's FCF Margin over 5 years: stood at 2134.01% in 2016, then surged by 70bps to 648.62% in 2017, then soared by 75bps to 161.07% in 2018, then dropped by -26bps to 202.24% in 2019, then crashed by -63bps to 330.18% in 2020.
  • Business Quant data shows FCF Margin for KALV at 330.18% in Q2 2020, 831.26% in Q1 2020, and 202.24% in Q4 2019.